US4970075A
(en)
*
|
1986-07-18 |
1990-11-13 |
Euroceltique, S.A. |
Controlled release bases for pharmaceuticals
|
US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5968551A
(en)
*
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US5681585A
(en)
*
|
1991-12-24 |
1997-10-28 |
Euro-Celtique, S.A. |
Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
IL119660A
(en)
|
1993-05-10 |
2002-09-12 |
Euro Celtique Sa |
Controlled release formulation comprising tramadol
|
US20070275062A1
(en)
*
|
1993-06-18 |
2007-11-29 |
Benjamin Oshlack |
Controlled release oxycodone compositions
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
IL110014A
(en)
*
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
IL109944A
(en)
*
|
1993-07-01 |
1998-12-06 |
Euro Celtique Sa |
Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
EP1442745A1
(de)
*
|
1993-10-07 |
2004-08-04 |
Euro-Celtique |
Oral anzuwendende opioidhaltige Zusammensetzungen mit verlängerter Wirkung
|
KR100354702B1
(ko)
*
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
US5891471A
(en)
*
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
US5843480A
(en)
*
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
US5430021A
(en)
*
|
1994-03-18 |
1995-07-04 |
Pharmavene, Inc. |
Hydrophobic drug delivery systems
|
US5484608A
(en)
*
|
1994-03-28 |
1996-01-16 |
Pharmavene, Inc. |
Sustained-release drug delivery system
|
ES2097087B1
(es)
*
|
1994-08-01 |
1997-12-16 |
Univ Sevilla |
Sistema de liberacion controlada de morfina y otros farmacos solubles en agua por complejacion con sustancias polimericas.
|
GB9422154D0
(en)
*
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
GB9519363D0
(en)
|
1995-09-22 |
1995-11-22 |
Euro Celtique Sa |
Pharmaceutical formulation
|
US5811126A
(en)
*
|
1995-10-02 |
1998-09-22 |
Euro-Celtique, S.A. |
Controlled release matrix for pharmaceuticals
|
JPH1050306A
(ja)
*
|
1996-07-31 |
1998-02-20 |
Toyota Autom Loom Works Ltd |
水素吸蔵合金電極の製造方法
|
DK1041987T3
(da)
*
|
1997-12-22 |
2006-08-21 |
Euro Celtique Sa |
Oral farmaceutisk doseringsform omfattende en kombination af en opioid-agonist og naltrexon
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
WO2000016776A1
(fr)
*
|
1998-09-18 |
2000-03-30 |
Takeda Chemical Industries, Ltd. |
Preparations a administrer par voie buccale a liberation lente
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
KR101216270B1
(ko)
*
|
1999-10-29 |
2012-12-31 |
유로-셀티크 소시에떼 아노뉨 |
서방성 하이드로코돈 제형
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
DK1255547T3
(da)
|
2000-02-08 |
2008-12-01 |
Euro Celtique Sa |
Kontrolleret-frigivelsessammensætninger indeholdende opioid-agonist og antagonist
|
RS50407B
(sr)
|
2000-02-08 |
2009-12-31 |
Euro-Celtique S.A., |
Oralne formulacije opijatnog agonista otporne na mehaničke,termičke i/ili hemijske promene fizičkih osobina doznog oblika
|
AU2002227383B2
(en)
|
2000-10-30 |
2004-07-08 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
UA81224C2
(uk)
*
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
ES2361148T3
(es)
|
2001-05-11 |
2011-06-14 |
Endo Pharmaceuticals Inc. |
Forma de dosificación de opioides de liberación controlada resistente al abuso.
|
EP1406630A1
(de)
*
|
2001-07-06 |
2004-04-14 |
Endo Pharmaceuticals Inc. |
Parenterale verabreichung von hydroxy-oxymorphon als analgetikum
|
US8329216B2
(en)
*
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
ATE376832T1
(de)
*
|
2001-07-06 |
2007-11-15 |
Penwest Pharmaceuticals Co |
Verzögert freisetzende formulierungen von oxymorphon
|
CA2454328C
(en)
|
2001-07-18 |
2008-03-18 |
Christopher D. Breder |
Pharmaceutical combinations of oxycodone and naloxone
|
WO2003013433A2
(en)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
MXPA04001210A
(es)
|
2001-08-06 |
2004-07-08 |
Euro Celtique Sa |
Formulaciones de agonista opioide con antagonista liberable y aislado.
|
US20030091635A1
(en)
*
|
2001-09-26 |
2003-05-15 |
Baichwal Anand R. |
Opioid formulations having reduced potential for abuse
|
CN102813654A
(zh)
|
2002-04-05 |
2012-12-12 |
欧洲凯尔蒂克公司 |
含有羟氢可待酮和烯丙羟吗啡酮的药物制剂
|
GB0209265D0
(en)
|
2002-04-23 |
2002-06-05 |
Novartis Ag |
Organic compounds
|
US20050106249A1
(en)
*
|
2002-04-29 |
2005-05-19 |
Stephen Hwang |
Once-a-day, oral, controlled-release, oxycodone dosage forms
|
ES2320435T3
(es)
*
|
2002-04-29 |
2009-05-22 |
Alza Corporation |
Metodo y formas de dosificacion para la administracion controlada de oxicodona.
|
MXPA04012021A
(es)
*
|
2002-05-31 |
2005-08-16 |
Johnson & Johnson |
Formas de dosis y composiciones para la administracion osmotica de dosis variables de oxicodona.
|
US20040001889A1
(en)
|
2002-06-25 |
2004-01-01 |
Guohua Chen |
Short duration depot formulations
|
US8557291B2
(en)
|
2002-07-05 |
2013-10-15 |
Collegium Pharmaceutical, Inc. |
Abuse-deterrent pharmaceutical compositions of opioids and other drugs
|
US10004729B2
(en)
|
2002-07-05 |
2018-06-26 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
EP1594467A4
(de)
*
|
2002-07-05 |
2008-10-22 |
Collegium Pharmaceutical Inc |
Missbrauch verhindernde pharmazeutische zusammensetzungen von opioiden und anderen medikamenten
|
US8840928B2
(en)
|
2002-07-05 |
2014-09-23 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
US20050020613A1
(en)
*
|
2002-09-20 |
2005-01-27 |
Alpharma, Inc. |
Sustained release opioid formulations and method of use
|
PT1551372T
(pt)
|
2002-09-20 |
2018-07-23 |
Alpharma Pharmaceuticals Llc |
Subunidade de sequestração e composições e métodos relacionados
|
US20040110781A1
(en)
*
|
2002-12-05 |
2004-06-10 |
Harmon Troy M. |
Pharmaceutical compositions containing indistinguishable drug components
|
EP2218448B1
(de)
|
2002-12-13 |
2015-09-23 |
Durect Corporation |
Orale Darreichungsform mit flüssigen hochviskose Trägersystemen
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
EP1479381A1
(de)
*
|
2003-05-19 |
2004-11-24 |
Euro-Celtique S.A. |
Pharmazeutische Zusammensetzung enthaltend eine feste Lösung
|
US20060165790A1
(en)
*
|
2003-06-27 |
2006-07-27 |
Malcolm Walden |
Multiparticulates
|
TWI357815B
(en)
*
|
2003-06-27 |
2012-02-11 |
Euro Celtique Sa |
Multiparticulates
|
SI1663229T1
(sl)
|
2003-09-25 |
2010-08-31 |
Euro Celtique Sa |
Farmacevtske kombinacije hidrokodona in naltreksona
|
CA2541371C
(en)
*
|
2003-10-03 |
2014-12-16 |
Atul M. Mehta |
Extended release formulations of opioids and method of use thereof
|
DK1691811T3
(da)
|
2003-12-11 |
2014-10-20 |
Sunovion Pharmaceuticals Inc |
Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
|
KR100963914B1
(ko)
*
|
2004-03-30 |
2010-06-17 |
유로-셀띠끄 소시에떼 아노님 |
흡착제 및 억제제를 포함하는 내변조성 제형
|
TW201509943A
(zh)
|
2004-03-30 |
2015-03-16 |
Euro Celtique Sa |
含有小於25ppm14-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
|
US20050226929A1
(en)
*
|
2004-04-12 |
2005-10-13 |
Jianbo Xie |
Controlled release opioid analgesic formulation
|
US20050266082A1
(en)
*
|
2004-05-26 |
2005-12-01 |
Patel Satishkumar A |
Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
|
EP1604667A1
(de)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioide zur Behandlung des Restless Leg Syndroms
|
EP1604666A1
(de)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
|
EP1765292B1
(de)
*
|
2004-06-12 |
2017-10-04 |
Collegium Pharmaceutical, Inc. |
Gegen missbrauch gesicherte arzneimittelformulierungen
|
US9308164B2
(en)
|
2004-06-30 |
2016-04-12 |
Sovereign Pharmaceuticals, Llc |
Hyoscyamine dosage form
|
GB2418854B
(en)
|
2004-08-31 |
2009-12-23 |
Euro Celtique Sa |
Multiparticulates
|
ES2496765T3
(es)
*
|
2004-09-17 |
2014-09-19 |
Durect Corporation |
Composición anestésica local prolongada que contiene SAIB
|
TWI369203B
(en)
|
2004-11-22 |
2012-08-01 |
Euro Celtique Sa |
Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
|
MX2007009162A
(es)
*
|
2005-01-28 |
2007-10-23 |
Euro Celtique Sa |
Formas de dosis rsistente al alcohol.
|
EP1695700A1
(de)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Darreichungsform enthaltend Oxycodon und Naloxon
|
EP1702558A1
(de)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Verfahren und Vorrichtung zur Darmtätigkeitserfassung
|
US20090214640A1
(en)
*
|
2005-03-04 |
2009-08-27 |
Intelgenx Cporp. |
Delayed release pharmaceutical oral dosage form and method of making same
|
MY148074A
(en)
*
|
2005-05-10 |
2013-02-28 |
Novartis Ag |
Pharmaceutical compositions comprising imatinib and a release retardant
|
JP2008542419A
(ja)
*
|
2005-06-09 |
2008-11-27 |
ユーロ−セルティーク エス.エイ. |
神経刺激性ステロイドの医薬組成物及びその使用
|
TWI366460B
(en)
*
|
2005-06-16 |
2012-06-21 |
Euro Celtique Sa |
Cannabinoid active pharmaceutical ingredient for improved dosage forms
|
CA2578626C
(en)
|
2005-06-27 |
2011-07-19 |
Biovail Laboratories International S.R.L. |
Modified-release formulations of a bupropion salt
|
US20070027105A1
(en)
|
2005-07-26 |
2007-02-01 |
Alza Corporation |
Peroxide removal from drug delivery vehicle
|
EP1813276A1
(de)
*
|
2006-01-27 |
2007-08-01 |
Euro-Celtique S.A. |
Manipulationssichere Dosierformen
|
US20070190141A1
(en)
*
|
2006-02-16 |
2007-08-16 |
Aaron Dely |
Extended release opiate composition
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
US20070281016A1
(en)
*
|
2006-06-06 |
2007-12-06 |
Endo Pharmaceuticals Inc., A Delaware Corporation |
Sustained release oxycodone composition with acrylic polymer and surfactant
|
US20070281017A1
(en)
*
|
2006-06-06 |
2007-12-06 |
Endo Pharmaceuticals Inc., A Delaware Corporation |
Sustained release oxycodone composition with acrylic polymer and metal hydroxide
|
US20080069891A1
(en)
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
EP2526932B1
(de)
|
2006-06-19 |
2017-06-07 |
Alpharma Pharmaceuticals LLC |
Pharmazeutische Zusammensetzung
|
WO2008011595A2
(en)
*
|
2006-07-21 |
2008-01-24 |
Lab International Srl |
Hydrophobic abuse deterrent delivery system
|
US7872013B2
(en)
*
|
2006-08-16 |
2011-01-18 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of opioid analgesics
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
ES2388355T3
(es)
|
2006-11-03 |
2012-10-11 |
Durect Corporation |
Sistemas de suministro transdémico que comprenden bupivacaína
|
US20080220064A1
(en)
*
|
2006-12-06 |
2008-09-11 |
Ramesh Ketkar Anant |
Extended release matrix formulations of morphine
|
GB0624880D0
(en)
*
|
2006-12-14 |
2007-01-24 |
Johnson Matthey Plc |
Improved method for making analgesics
|
US8202542B1
(en)
|
2007-05-31 |
2012-06-19 |
Tris Pharma |
Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
US8415401B2
(en)
|
2007-12-06 |
2013-04-09 |
Durect Corporation |
Oral pharmaceutical dosage forms
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US20090246276A1
(en)
|
2008-01-28 |
2009-10-01 |
Graham Jackson |
Pharmaceutical Compositions
|
US20100003322A1
(en)
*
|
2008-07-03 |
2010-01-07 |
Lai Felix S |
Enteric coated hydrophobic matrix formulation
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
WO2010103039A1
(en)
|
2009-03-10 |
2010-09-16 |
Euro-Celtique S.A. |
Immediate release pharmaceutical compositions comprising oxycodone and naloxone
|
FR2946533A1
(fr)
|
2009-06-12 |
2010-12-17 |
Ethypharm Sa |
Reduction des fluctuations plasmatiques d'opioides.
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
MX2012012991A
(es)
|
2010-05-11 |
2012-11-30 |
Cima Labs Inc |
Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol.
|
CA2991217C
(en)
|
2010-12-22 |
2020-06-09 |
Purdue Pharma L.P. |
Encased tamper resistant controlled release dosage forms
|
JP5638151B2
(ja)
|
2010-12-23 |
2014-12-10 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
不正加工抵抗性の(tamperresistant)固形経口剤形
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
TWI522101B
(zh)
|
2012-04-17 |
2016-02-21 |
普渡製藥有限合夥事業 |
處理由類鴉片引起之不利的藥效動力反應之系統和方法
|
CA2879268C
(en)
|
2012-07-16 |
2018-05-08 |
Rhodes Technologies |
Process for improved opioid synthesis
|
KR101946103B1
(ko)
|
2012-07-16 |
2019-02-08 |
로드스 테크놀로지즈 |
개선된 오피오이드 합성을 위한 방법
|
BR112015017451B1
(pt)
|
2013-02-05 |
2023-01-10 |
Purdue Pharma L.P. |
Formulações farmacêuticas resistentes à violação
|
US9572885B2
(en)
|
2013-03-15 |
2017-02-21 |
Durect Corporation |
Compositions with a rheological modifier to reduce dissolution variability
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
EP3003297A4
(de)
|
2013-06-05 |
2017-04-19 |
Synchroneuron Inc. |
Acamprosat-formulierungen, verfahren zur verwendung davon und kombinationen damit
|
CA2918004C
(en)
|
2013-07-23 |
2018-11-20 |
Euro-Celtique S.A. |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
BR112016002079A2
(pt)
|
2013-08-02 |
2017-09-05 |
Johnson Matthey Plc |
Processo para preparação de um aditivo ácido de oximorfona, solução aquosa de aditivo ácido de oximorfona, aditivo ácido de oximorfona sólido, e, alcaloide de oximorfona sólido
|
CA2937006C
(en)
|
2014-01-15 |
2018-12-04 |
Rhodes Technologies |
Process for improved oxycodone synthesis
|
CA2937007C
(en)
|
2014-01-15 |
2018-11-06 |
Rhodes Technologies |
Process for improved oxymorphone synthesis
|
US9062063B1
(en)
|
2014-03-21 |
2015-06-23 |
Johnson Matthey Public Limited Company |
Forms of oxymorphone hydrochloride
|
US9849124B2
(en)
|
2014-10-17 |
2017-12-26 |
Purdue Pharma L.P. |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
US9918979B2
(en)
|
2015-01-29 |
2018-03-20 |
Johnson Matthey Public Limited Company |
Process of preparing low ABUK oxymorphone hydrochloride
|
US9861629B1
(en)
|
2015-10-07 |
2018-01-09 |
Banner Life Sciences Llc |
Opioid abuse deterrent dosage forms
|
US20180303757A1
(en)
|
2015-10-23 |
2018-10-25 |
Kashiv Pharma Llc |
Enhanced abuse-deterrent formulations of oxycodone
|
US10335405B1
(en)
|
2016-05-04 |
2019-07-02 |
Patheon Softgels, Inc. |
Non-burst releasing pharmaceutical composition
|
WO2017222575A1
(en)
|
2016-06-23 |
2017-12-28 |
Collegium Pharmaceutical, Inc. |
Process of making more stable abuse-deterrent oral formulations
|
US10335375B2
(en)
|
2017-05-30 |
2019-07-02 |
Patheon Softgels, Inc. |
Anti-overingestion abuse deterrent compositions
|
EP3703724A1
(de)
|
2017-11-02 |
2020-09-09 |
NatureCeuticals Sdn. Bhd. |
Extrakt aus orthosiphon stamineus, formulierungen und verwendungen davon
|
KR20220140711A
(ko)
|
2020-01-13 |
2022-10-18 |
듀렉트 코퍼레이션 |
불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
|
KR20230000634U
(ko)
|
2021-09-16 |
2023-03-23 |
장상환 |
분리가능한 쇠스랑
|